Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS)

Detalles Bibliográficos
Autores principales: Neubauer, Andreas, Wiesmann, Thomas, Vogelmeier, Claus F., Mack, Elisabeth, Skevaki, Chrysanthi, Gaik, Christine, Keller, Christian, Figiel, Jens, Sohlbach, Kristina, Rolfes, Caroline, Renz, Harald, Wulf, Hinnerk, Burchert, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7298698/
https://www.ncbi.nlm.nih.gov/pubmed/32555296
http://dx.doi.org/10.1038/s41375-020-0907-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7298698/
https://www.ncbi.nlm.nih.gov/pubmed/32555296
http://dx.doi.org/10.1038/s41375-020-0907-9

Ejemplares similares